Brief: Ascentage Pharma Group International Says European Commission Granted Its Core Drug Candidate HQP1351 (Olverembatinib) Orphan Designation
22/11/2021 13:47
Nov 22 (Reuters) - Ascentage Pharma Group International
6855.HK :
* EUROPEAN COMMISSION GRANTED CO'S CORE DRUG CANDIDATE
HQP1351
(OLVEREMBATINIB) ORPHAN DESIGNATION
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up